Why the study?
Inclisiran is a novel PCSK9 inhibitor, and this study aimed to explore its safety profiles.
Does inclisiran have a different safety profile compared to other PCSK9 inhibitors in real-world data?
Does inclisiran have a different safety profile compared to other PCSK9 inhibitors in real-world data?
Inclisiran exhibits a distinct real-world safety profile compared to other PCSK9 inhibitors, with higher rates of gastrointestinal and infectious adverse events but fewer injection site and skin reactions.
Answers are grounded in this paper and cite their sources.
Clinicians should monitor inclisiran signals; this FAERS analysis leaves causal risks open pending prospective confirmation.
BACKGROUND: Inclisiran is a novel inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). This study aimed to explore its safety profiles. RESEARCH DESIGN AND METHODS: Reports from FDA Adverse Event Reporting System were collected and analyzed from January 2021 to September 2023. The ROR method was employed to detect safety signals. Comparative analysis was conducted at levels of SOCs, HLGTs, and PTs with other PCSK9 inhibitors. RESULTS: A total of 136 safety signals were identified, and the majority were novel. In comparison with other PCSK9 inhibitors, inclisiran had a greater number of adverse drug events in 'Gastrointestinal disorders' and 'Infections and infestations.' 'Gastrointestinal symptoms and motility' and 'respiratory and urinary tract infections' are the principal causes for the aforementioned safety issues. Nevertheless, inclisiran demonstrates potential advantages in terms of safety, particularly in 'Eye disorders,' 'Skin and subcutaneous tissue disorders' and 'General disorders and administration site condition.' CONCLUSION: Due to distinctive pharmacological mechanism of action, the safety issues of inclisiran merit meticulous consideration. There are some safety profile tendencies that differ from other PCSK9 inhibitors. Therefore, special attention should be paid to its administration in high-risk populations. Additionally, some results remain uncertain, requiring further verification.
No takes yet. Share an insight, caveat, or question.
Su et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: